论文部分内容阅读
在过去的10年间,血管紧张素转换酶抑制剂(ACEI)在控制高血压和心力衰竭方面起了重要作用,但是,应用这类药物的客观指征尚未十分明确。高血压:ACEI在治疗高血压中确实起了重要作用。ACEI能有效地降低血压,并且因其较少代谢性副作用而可能更为有效。因此,有人推荐作为治疗高血压的第一线药物。ACEI确能减慢高血压和糖尿病患者的肾功能减退,但未能证明可减少透析或肾移植的需求。尚无证据说明ACEI可降低高血压病人的病死率和病残率。许多病人采用标准的治疗如β-阻滞剂或利尿剂时有副作用;不少病人不愿长期服用这类药物;另外一些病人单用β阻滞剂或利
Over the past 10 years, angiotensin-converting enzyme inhibitors (ACEIs) have played an important role in the control of hypertension and heart failure, but the objective indications for the use of these drugs are not yet clear. Hypertension: ACEI does play an important role in the treatment of hypertension. ACEI can effectively lower blood pressure, and may be more effective because of its less metabolic side effects. Therefore, it is recommended as a first-line treatment of hypertension drugs. ACEI does slow down renal dysfunction in people with hypertension and diabetes but has failed to demonstrate the need to reduce dialysis or kidney transplants. There is no evidence that ACEI can reduce the mortality and morbidity of hypertensive patients. Many patients have side effects when using standard treatments such as beta-blockers or diuretics; many are reluctant to take these drugs for long periods of time; others use beta blockers or